Executive Summary: State of the Industry
Tim Hunt, CEO of the Alliance for Regenerative Medicine (ARM), kicked off the event with a briefing on the state of the cell and gene therapy development landscape. With 475 members worldwide, ARM focuses on convening the sector, providing data and analysis, engaging with stakeholders, and enabling the development of advanced therapies. One of their key initiatives is modernizing healthcare systems to enable access to these novel therapeutics. Highlights of this briefing are provided in this summary.
White Paper: mRNA Innovation Is Revolutionizing Disease Prevention
The first FDA approved mRNA product was decades in the making, following many iterations throughout history the first mRNA vaccine in the US was brought to life. This achievement delivered aid to patients and healthcare providers during the most critical public health crisis in recent years. Since then, researchers have been operating at incredible speeds to develop more novel mRNA treatment options for patients, across many indications.
In this white paper, Anshul Mangal, President of Project Farma & Precision ADVANCE and Chad Salisbury, Senior Vice President of Project Farma (PF), discuss the mRNA revolution and its impact on the future of disease prevention and treatment.
White Paper: “Preventative” Gene Therapies: Perspectives on Payer Access Challenges and Solutions
Gene therapies offer hope for patients with severe genetic diseases by providing long-term benefits and even cures. However, the challenges of evaluating the long-term benefits of these therapies from a payer perspective are considerable. This white paper by PRECISIONadvisors highlights the shift of gene therapy research into more prevalent diseases, and outlines how manufacturers and payers can co—create evidence requirements and models to optimize launch success and sustainability.
On Demand: NICE Early Scientific Advice: When, Why, and How!
Have you considered using NICE Scientific Advice (SA) to inform your evidence development, trial design, and/or economic modelling? Are you familiar with the concept of NICE SA, but have no direct experience? Or have you used the process before, but want to learn how to optimise your use of it?
Join PRECISIONadvisors on July 26 at 9am EST for a complimentary webinar, as we share our experience with NICE SA in a pragmatic discussion of what it can do for you, and best practices for getting the most from NICE SA.
Article: Innovation in Gene Therapies
Despite innovation to date in gene therapy, safety concerns with adeno-associated virus (AAV) vectors and uneasiness around cost and affordability has brought into focus the need for even more advancement in the field. In this Pharma Live article Precision’s Phil Cyr discusses some of the innovations that are occurring to address these issues.
On Demand: Consequences of the IRA on Oncology Care Providers
The goal of this complimentary webinar is to increase understanding of how the IRA impacts your customers…viewing it through their eyes. You will gain insights from experts representing both provider and policy perspectives as they discuss:
- What portions of the IRA are important to oncology?
- What are the possible positive, negative, and unintended consequences of the IRA?
- How are community practices and hospital outpatient departments preparing?
- What is the operational impact of IRA?
- What role if any should the pharmaceutical company play?
White Paper: Moving CGTx Clinical Development Forward in 2023
Clinical trials are foundational to developing innovative, life-saving treatments and cures for patients. For developers of cell and gene therapy (CGTx) products, the path to clinical success is fraught with vast and complex challenges. The CGTx field is becoming more crowded, with increased clinical trial volume and an influx of less-experienced sponsors contributing to an increase in clinical holds in the category. Such challenges intensify the pressure to succeed in a fiercely competitive environment.
White Paper: Market Trends and Expectations for Advanced Therapies in 2023
The cell and gene therapy space has undergone transformational change in the last few years, driven by the promise these modalities have demonstrated in addressing rare and intractable diseases. Achievements in the CAR-T therapy space – there are now six approved CAR-T treatments on the market – in conjunction with breakthroughs in gene therapy and viral vector drugs, have signaled a new era of innovation aimed at furthering cell and gene therapies within the greater healthcare landscape.
This white paper is based on a panel discussion hosted by Precision ADVANCE, experts from across the cell and gene therapy sector convened to explore the ways their organizations have met headlong the challenges and opportunities that typify cell and gene therapy development. Panelists for the event included:
- Andy Kinley, Vice President, Innovation and Clinical Science, Precision for Medicine
- Peter Andersen, Chief Scientific Officer, Vita Therapeutics
- Deborah Phippard, Chief Scientific Officer, Precision for Medicine
- Palani Palaniappan, Chief Technology Officer, Pioneering Medicines, Flagship Pioneering
- Phil Cyr, Senior Vice President, Precision Value & Health
- Charlie Harper, Vice President, Project Farma
White Paper: Gene Editing Breakthroughs: A New Hope for Patients
Gene editing technology has rapidly evolved over the past decade. From the initial breakthrough of sequencing the first human genome to researchers today having the ability to create genetically modified mice in as little as four weeks. CRISPR Cas-based gene editing, which acts as a pair of genomic scissors, is at the core of these innovations. The revolutionary technology has enabled rapid genome sequencing and editing to spur advancements in disease research and treatment.
In this white paper, Anshul Mangal President of Project Farma and Precision ADVANCE and Cynthia Pussinen, Advisor & Executive Consulting Partner share how the latest breakthroughs in gene editing technology have the potential to dramatically improve outcomes for patients.
Three PRECISION agencies are ranked in MM+M’s Top 100 North American healthcare agencies of 2023
Three Precision agencies – PRECISIONvalue, PRECISIONeffect and PRECISIONscientia – each rank as one of MM+M’s Top 100 North American healthcare agencies of 2023.